Here are the 10-K annual reports from IN8bio, Inc. (INAB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INAB filings page.
IN8bio, Inc. files its annual report describing a focused gamma‑delta T cell therapy pipeline alongside a going concern warning. The company is developing allogeneic and autologous gamma‑delta T cell products and T cell engagers for cancers and autoimmune diseases, highlighted by INB‑100 for high‑risk leukemias and INB‑200/INB‑400 for newly diagnosed glioblastoma.
Early clinical data show durable remissions in AML patients after haploidentical transplants and extended progression‑free survival in glioblastoma versus standard therapy. IN8bio reported cash of $27.1 million as of December 31 2025 and expects this to fund operations only into April 2027, leading management to state substantial doubt about its ability to continue as a going concern without additional capital or strategic transactions.